• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Technology Bio Tech

Why Australian Vaccine News Will Be Met with a Shrug from the ASX

Like 0

By Lachlann Tierney, Wednesday, 26 August 2020

It’s a strange one, as I write this, ASX 200 futures are pointing to a down day for the index. This, as promising news emerges from the University of Queensland’s (UQ) COVID-19 vaccine project. Here’s what you should know about the Australian vaccine..

It’s a strange one, as I write this, ASX 200 futures are pointing to a down day for the index.

This, as promising news emerges from the University of Queensland’s (UQ) COVID-19 vaccine project.

Here’s what you should know about the Australian vaccine:

  • Early data suggests ‘absolutely no safety concerns’
  • The vaccine made neutralising antibodies and created a strong T-cell response
  • Data released to international standard
  • Allows for benchmarking of other vaccine candidates

Keith Chappell, one of the leaders of UQ vaccine project, is quoted in the Australian Financial Review as saying:

‘All the results today show that it’s safe and likely to provide protection against both the virus infection and the symptoms of disease.’

So, what does the Australian market think of this development with a vaccine?

Not much, doesn’t matter, and let’s see the latest earnings numbers.

What’s going on here?

The AI ‘mega-trend’ – four ways you could profit. Learn More.

US market favours the tech giants on positive vaccine news days

The US indices like the S&P 500 [SPX] and the NASDAQ Composite [IXIC] are at all-time highs and previously pushed higher on any shred of positive vaccine news.

Often (in the US at least) on the day of positive news like this, investors continue to pile into the tech giants.

This includes Facebook Inc [NASDAQ:FB], Amazon Inc [NASDAQ:AMZN], Apple Inc [NASDAQ:APPL], Microsoft Corporation [NASDAQ:MSFT], and Netflix Inc [NASDAQ:NFLX].

The big winner? Tesla Inc [NASDAQ:TSLA], with a mammoth 500% rise from the March market lows.

But as the ASX is set to shrug at the good news, here’s a look at what the ASX 200 [XJO] did over the last 10 weeks:


Port Phillip Publishing

Source: tradingview.com

[Click to open in a new window]

As you can see in the above chart, since 27 May the sideways trading took place in a range of less than 9%.

This shows up in a narrowing of the 20- and 50-day moving averages.

Now you may be thinking, a big move down may be on the cards.

And that your dreams of BetaShares Australian Equities Strong Bear Hedge Fund [ASX:BBOZ] riches may come true.

I’m not convinced.

Australian market has fewer defensive options

Like a good joke, the market is all about expectations, and the sideways trading from the March market lows was likely anticipating a mixed bag of earnings.

Results during this earnings season reflect just that.

Some companies are doing well, others are flailing.

And Australia’s tech sector is far less developed than the US’ so there are less places for capital to accumulate as investors go defensive.

I think the US tech giants are now a defensive play as opposed to a growth play.

They are at the tail end of a mature megatrend and with sizeable cash reserves, and a captive audience like the supermarkets, they tend to attract money regardless of their earnings multiple.

On the ASX, some of the major winners from the market lows are companies like Coles Group Ltd [ASX:COL], Afterpay Ltd [ASX:APT], and Xero Ltd [ASX:XRO].

So, there are similarities between the US markets and the ASX in terms of the favoured plays during the pandemic.

It’s just that we have less options in Australia when it comes to supposedly ‘safe’ companies.

The thing to remember here, is that with less options, the capital is increasingly flowing towards small-caps.

Because it must go somewhere.

Keep dreaming BBOZers, small-caps are where it’s at

In Australia this shows up as the S&P/ASX Small Ordinaries [XSO] catching up to the ASX 200 [XJO].

As someone who spends all day delving into the small-cap world, I can assure you there are some big moves afoot in some of these companies.

It’s part of why our Exponential Stock Investor service has had recent success.

Of course, the highly volatile nature of small-caps means they are potentially riskier, but you should be prepared to pounce on whatever the market throws up.

The shift to value investing over growth investing is not showing up in the charts just yet.

So, I expect the ASX to continue to move sideways for a reasonable period as the earnings results continue to flow.

I also don’t expect the next major move for the ASX 200 to be a plunge into the abyss either.

If anything, I expect it may be dragged slightly further upwards should US stimulus get over the line combined with a successful lockdown in Melbourne.

For now, keep dreaming BBOZers.

Regards,

Lachlann Tierney Signature

Lachlann Tierney,
For Money Morning

PS: Four Well-Positioned Small-Cap Stocks — These innovative Aussie companies are well placed to capitalise on post-lockdown megatrends. Click here to learn more.

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Comments

Subscribe
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments
Lachlann Tierney
Lachlann ‘Lachy’ Tierney is passionate about uncovering hidden opportunities in the microcap sector. With four years of experience as a senior equities analyst at one of Australia’s leading microcap firms, he has built a reputation for rigorous research, deep-dive due diligence, and accessible investor communications. Over this time, he has vetted seed, pre-IPO and ASX-listed companies across sectors, conducted onsite visits, and built strong relationships across the microcap space. Lachy is nearing completion of a PhD in economics at RMIT University, where his research focuses on blockchain governance and voting systems. His work is housed within the Blockchain Innovation Hub at RMIT, a leading research centre for crypto-economics and blockchain research. He holds a Master’s degree from the London School of Economics and an Honours BA in Philosophy and Politics from the University of Melbourne. Born in New York and raised in California, Lachy grew up a few blocks from biotech giant Amgen and counts among his peers various characters in the overlapping worlds of venture capital, technology and crypto. When he’s not researching microcaps, he’s most likely sweating it out in a sauna or dunking himself in cold Tasmanian water.

Lachlann’s Premium Subscriptions

Publication logo
Australian Small-Cap Investigator
Publication logo
Fat Tail Microcaps
Publication logo
James Altucher’s Early-Stage Crypto Investor Australia

Latest Articles

  • Why ‘One-Hit Wonder’ Explorers Will Burn Your Money: The Repeatability Test
    By James Cooper

    In James Cooper’s ongoing series about ‘geology for investors, ’ he details why grades aren’t the only factor in exploration success.

  • Cassandra Goes Unheard
    By Charlie Ormond

    Michael Burry from ‘The Big Short’ has emerged into the public eye with fresh bubble warnings. But once again, his warnings are ‘uninvited and unwelcome’ to the market.

  • ASX About to Crack?
    By Murray Dawes

    In today’s Closing Bell, we look at the ASX 200’s sudden slide, why key support is so important here, and how a false break could turn into a near 10% correction into Christmas. I also touch on the growing cracks in weaker AI names, such as Oracle and Meta, and what that might mean for the broader market. We finish on a positive note with a brief look at the lithium stocks that are still running. Hit play to see the levels and charts I’m watching now.

Primary Sidebar

Latest Articles

  • Why ‘One-Hit Wonder’ Explorers Will Burn Your Money: The Repeatability Test
  • Cassandra Goes Unheard
  • ASX About to Crack?
  • The Big Dig Returns
  • The K-Shaped Economy Spells Trouble

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988